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TLR2-dependent cellular signaling in Mycobacterium tuberculosis-infected
macrophages causes apoptosis and inhibits class II major histocompatibility
complex (MHC-II) molecules antigen processing, leading to evasion of surveillance.
Mycobacterium tuberculosis (MTB) lipoproteins are an important class of Toll-like
receptor (TLR) ligand, and identified as specific components that mediate these effects.
In this study, we identified and characterizedMTB lipoprotein Rv1016c (lpqT) as a cell wall
associated-protein that was exposed on the cell surface and enhanced the survival of
recombinants M. smegmatis_Rv1016c under stress conditions. We found that Rv1016c
lipoprotein was a novel TLR2 ligand and able to induce macrophage apoptosis in a
both dose- and time-dependent manner. Additionally, apoptosis induced by Rv1016c
was reserved in THP-1 cells blocked with anti-TLR-2 Abs or in TLR2−/− mouse
macrophages, indicating that Rv1016c-induced apoptosis is dependent on TLR2.
Moreover, we demonstrated that Rv1016c lipoprotein inhibited IFN-γ-induced MHC-II
expression and processing of soluble antigens in a TLR2 dependent manner. Class II
transactivator (CIITA) regulates MHC II expression. In this context, Rv1016c lipoprotein
diminished IFN-γ-induced expression of CIITA IV through TLR2 and MAPK Signaling.
TLR2-dependent apoptosis and inhibition of MHC-II Ag processing induced by Rv1016c
during mycobacteria infection may promote the release of residual bacilli from apoptotic
cells and decrease recognition by CD4+ T cells. These mechanisms may allow
intracellular MTB to evade immune surveillance and maintain chronic infection.
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INTRODUCTION
Mycobacterium tuberculosis (MTB) is considered to be the significant cause of mortality worldwide,
especially due to its ability to resistant antibiotic and co-infected with HIV patients (Bruchfeld
et al., 2015; Dheda et al., 2016). Host resistance against MTB infection depends on both innate
and adaptive immunity, and the emerging evidences in mammals have indicated that CD4+T cells
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initiates the adaptive response and are critical to control of MTB
infection, although CD8+T cells are also involved (Torrado and
Cooper, 2011; Jasenosky et al., 2015). However, MTB remains
to survival within infected macrophages for prolonged periods
by evading the elimination of host immune responses (Holvast
et al., 2010; Dorhoi and Kaufmann, 2014). The molecular basis
that allowMTB to persist for years in the face of vigorous CD4+T
cell responses may involve the decreased antigen processing or
MHC-II expression in infected macrophages, which prevented
the recognition of infected macrophages by effector CD4+T cells
(Noss et al., 2000; Kaufmann et al., 2016). Actually, MTB indeed
can inhibit antigen processing by murine macrophages via a
mechanism involving decreased synthesis of MHC-II molecules,
consistent with other reports of the ability of mycobacteria to
decrease MHC-II expression by infected cells (Kaufmann and
Schaible, 2005; Pecora et al., 2009; Satchidanandam et al., 2014).
Mycobacterium tuberculosis was capable of inducing
macrophages to undergo apoptosis in vitro. Recently, emerging
interest has arisen in the role of macrophage apoptosis in host
defense against MTB infection (Keane et al., 2000). However,
A variety of questions including the characterization of the
responsible microbial factors and the underlying apoptotic
mechanism involved remain unresolved. Knowledge about
the mechanisms involved in the apoptosis of mycobacteria-
infected macrophages suggested that M. tuberculosis could
interact with macrophages and induced apoptosis through TLR
signaling (Means et al., 2001). TLR-2 has been demonstrated to
recognizeM. tuberculosis or its subcellular fractions and activate
intracellular apoptotic signaling. A few of molecularly diverse
mycobacterial products involved in macrophage apoptosis have
been identified; among these are 19-kDa lipoprotein (Lopez
et al., 2003), ESAT6 (Derrick and Morris, 2007), lipomannan
(Dao et al., 2004), and 38-kDa lipoprotein (Sanchez et al., 2009).
Identification of M. tuberculosis factors responsible for inducing
apoptosis will facilitate the understanding of pathogenesis and
may provide novel strategies for MTB prevention or treatment.
TLR2 on APCs are critical for host protection and
immunopathology, particular in host APCs sensingmycobacteria
(Kleinnijenhuis et al., 2011). Previous studies showed that
deficiency in TLR2 could enhance the susceptibility of mice
to mycobacterial infection (Reiling et al., 2002; Gomes et al.,
2004). The TLR2 polymorphisms in human are also associated
with increased susceptibility to tuberculosis (Ogus et al., 2004;
Texereau et al., 2005; Dalgic et al., 2011). So far, several
mycobacterial ligands including lipoproteins have been found
to bind to TLR2 (Pennini et al., 2006; Shi et al., 2009). MTB
lipoproteins have either stimulatory or inhibitory effects on
host antigen presenting cells (APCs), some of which are TLR2
dependent (Harding and Boom, 2010). Lipoprotein MPT83, a
TLR2 ligand, promoted IFN-γ-induced MHC II expression and
enhanced the ability of macrophages to present the MPT83
Abbreviations: Ms, M. smegmatis; TLR, Toll-like receptors; TB, tuberculosis;
MTB, Mycobacterium tuberculosis; LPS, Lipopolysaccharides; CFU, colony-
forming unit; SDS-PAGE, sulfate-polyacrylamide gel electrophoresis; ELISA,
enzyme-linked immune sorbent assay; MHC, histocompatibility complex; IFN-γ,
Interferon gamma; Pam3, Pam3CSK4.
peptide to CD4+T by (Chen et al., 2012). However, prolonged
exposure to other lipoproteins such as Lpr A, Lpr G as
well as 19-kDa lipoproteins inhibited IFN-γ-induced MHC-II
expression and antigen presentation via TLR2 (Pecora et al., 2006;
Drage et al., 2010). Additionally, MTB lipoproteins inhibited
several IFN-γ-induced immune function genes expression
including II transactivator (CIITA), which regulates MHC II
transcription, H2-M, and other accessory proteins required for
Ag presentation, potentially inhibiting responses by CD4+T
cells that produce IFN-γ (Noss et al., 2001). Consequently,
a small group of infected macrophages with attenuated APC
function may induce anti-inflammatory cytokines and be unable
to present MTB antigens to CD4+T cells, providing a kind
of mechanism by which MTB consistently persists and evades
immune surveillance (Richardson et al., 2015).
Regulation of MHC-II expression or antigen processing can
be achieved by exposure of macrophages to MTB components,
which initiates responses by APCs that regulate both innate
and adaptive immunity (De Lerma Barbaro et al., 1999). So
far, only several MTB lipoproteins have been characterized
to modulate this process. Here, we characterized a novel
MTB lipoprotein Rv1016c, and determine its effects on host
macrophages. Our results showed that Rv1016c prolonged the
survival of recombinant M. smegmatis within host macrophages
and accelerated host cell apoptosis. We present evidences that
Rv1016c inhibited IFN-γ–induced antigen presentation and
MHC-II expression in macrophages dependent on TLR2. We
further demonstrated that Rv1016c lipoprotein inhibited IFN-γ-
induced expression of CIITA IV via TLR2 and MAPK Signaling.
Together, Rv1016c may involve mycobacterial virulence via a
mechanism, which induced apoptosis and diminished antigen
presentation to CD4+ T cells, contributing to immune evasion
byMycobacterium tuberculosis.
MATERIALS AND METHODS
Mice and Cell Lines
C57BL/6, TLR2 knockout, and TLR4 knockout mice were
obtained from the Model Animal Research of Nanjing University
(Nanjing, China), and they were housed under specific pathogen-
free conditions in the Animal Center of the School of Life Science
of Fudan University. All experimental procedures followed
the Guidelines for the Care and Use of Laboratory Animals
from the National Institutes of Health and were approved
by the Animal Care and Use Ethical Committee of Shanghai
Provence. THP-1 cell line was purchased from the Cell Bank
of the Chinese Academy of Sciences (Shanghai, China). Cells
were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
(Gibco, Grand Island, NY, USA) supplemented with 10% fetal
bovine serum (FBS), penicillin (100U/ml) and streptomycin
(100 mg/ml) and maintained at 37◦C in a humidified incubator
(5% CO2). PBMCs were isolated from whole blood with Ficoll-
Paque Plus (Amersham Biosciences, Piscataway, NJ). Monocytes
were prepared from PBMCs either by adherence or with the
Miltenyi monocyte isolation kit (Miltenyi Biotec, Auburn, CA),
and monocytes derived macrophages (MDMs) were obtained
as previously described (Dao et al., 2004). The resultant
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macrophages were used during the following week. DOBW T
hybridoma cells were used to detect OVA323−339 (Pai et al., 2003).
Abs and Reagents
Middlebrook 7H9, 7H10, and OADC were obtained from
Difco (Detroit, MI). Annexin V-PE was from BD PharMingen
(Mississauga, Ontario, Canada). OVA:I-Ab complexes were
detected with DOBW T hybridoma cells (Pai et al., 2003). Anti-
His was obtained from antibodies (Santa Cruz Biotechnology,
SantaCruz, USA). Anti-Rv1016c, Anti-Rv2145c and Anti-
Rv3425 mouse polyclonal antibody were from C57BL/6 mouse
immunized by synthesized respective peptides in our lab.
The primary Abs used included rabbit antiERK2, rabbit anti-
p38, rabbit anti-JNK, rabbit anti-phosphoERK1/2, rabbit anti-
phospho-p38, rabbit anti-phospho-JNK, rabbit anti-phospho-
IκBα, and peroxidase (HRP)-conjugated secondary Abs (Cell
Signaling Technology). Anti-TLR2 and anti-TLR4 were from
BioLegend. Alexa488-conjugated anti- His Abs, Alexa488-
conjugated or Alexa555-conjugated secondary antibodies were
obtained from (Cell Signaling Technology).
Expression of Recombinant Rv1016c and
Construction of M. smegmatis_Rv1016c
The MTB gene was amplified by PCR from H37Rv genomic
DNA using the forward primer 5′CCCAAGCTTGGGGAGGGC
ATCCGGCGGGCTTG3′ and the reverse primer 5′CGGGAT
CCCGGCCCCAACCGTGCGGACAAT3′, which contain a Hind
III site and a BamH I site, respectively. The amplified PCR
product was cloned into the vector pRSFDuet-1 (Novagene,
Madison, WI). The expression of the recombinant protein was
induced by adding isopropyl-β-thiogalactopyranoside (IPTG) to
a final concentration of 0.1 mM as previously described (Su
et al., 2015). Recombinant Rv1016c was purified using a HIS-
Select R© Nickel Affinity Gel (Sigma-Aldrich, St. Louis, MO, USA)
with minor modifications. Recombinant protein was dialyzed
against PBS (pH 7.4) and treated with Pierce High Capacity
Endotoxin Removal Resin (Pierce, USA) in accordance with
the user instructions to eliminate endotoxins. The endotoxin-
free Rv1016c protein was quantified with a bicinchoninic acid
(BCA) protein assay kit (Pierce, Rockford, IL, USA) and frozen
at −80◦C. Samples were subjected to SDS-PAGE, and the His-
tagged Rv1016c protein was detected by Western blotting using
mouse anti-his antibody or anti- Rv1016c.
The pNIT plasmid containing Rv1016c was electroporated
into M. smegmatis. The selected M. smegmatis_Rv1016c
(Ms_Rv1016c) transformants were cultured in Middlebrook 7H9
with 10% oleic albumin dextrose catalase (OADC) containing
50 µg/ml kanamycin. The Ms_Rv1016c strain was identified by
immunoblotting using anti- Rv1016c mouse polyclonal anti-
serum. The vector pNIT was electroporated into M. smegmatis
to generate Ms_ pNIT strain as a control.
Localization of the Rv1016c Protein
MTB H37Rv and Ms_Rv1016c were grown, and subcellular
fractionation of Rv1016c protein was performed as previously
described (Xu et al., 2015). Briefly, the cells were lysed by
sonification for 30 min, and the lysates were centrifuged
at 11,000 g for 5 min at 4◦C to precipitate cellular debris
and those unlysed cells. The supernatant was subjected to
ultracentrifugation at 27,000 × g for 40 min at 4◦C to recover
cell wall-associated proteins. The supernatant was dell membrane
and cytosol fractions. Each fraction was subjected to Western
blotting using anti-Rv1016c mouse polyclonal antibody.
Proteinase K degradation assay was performed as previously
described (Xu et al., 2015). Briefly, the recombinant Ms_Rv1016c
were treated with proteinase K at a concentration of 100 µg/ml
and incubated at 37◦C for the indicated times. The reaction was
stopped by the addition of protease inhibitor Cocktail Tablets
(Roche, Basel, Switzerland). Finally, each sample was analyzed by
Western blotting using anti-Rv1016c and anti-Rv2145c Abs (as a
cytoplasmic protein control).
Intracellular Survival Assay
THP-1 cells (1 × 106 cells per well) were cultured in 6-well
tissue plates. Following 48 h of treatment with 0.1 mg/ml of
phorbol 12-myristate-13-acetate (PMA) (Sigma), THP-1 cells
were transformed into an adherent state. Cells were infected with
Ms_Rv1016c or Ms_pNIT at an MOI of 10. Four hours after
infection, macrophages were incubated with a final concentration
of 2 µg/ml hygromycin for 2 h. At indicated time after
infection, macrophages were then washed twice and lysed in
sterile water containing 0.025 % (v/v) SDS. The lysed cells were
plated on 7H10 agar plates, and the colony forming units were
determined as a measure of intracellular survival of recombinant
M. smegmatis.
The survival of Ms_Rv1016c under different stress conditions
was performed as previously described (Li et al., 2016). Briefly,
the disk diffusion method was used to qualitatively measure the
differences in H2O2 and SDS sensitivities between Ms_Rv1016c
and Ms_pNIT. The indicated amount of H2O2 and SDS was
spotted on 5.5mm-diameter Whatman filter disks placed on
the bacterial lawn. After 3–4 days incubation, the diameter of
zone of complete inhibition was measured. All experiments were
performed at least three times.
Apoptosis Assays
Apoptosis was assayed by either TUNEL assay or annexin V-
PE staining as previously described (Lopez et al., 2003). TUNEL
assays were analyzed using BD PharMingen kit (Mississauga,
Ontario, Canada), according to the manufacturer’s instructions.
Cells were considered apoptotic if they were TUNEL positive
(green fluorescent nuclear staining). Cells incubated with
actinomycin D were as positive controls. For annexin V-PE
assays, cells were treated with annexin V-PE buffer (10 mM
HEPES, pH 7.4), and then incubated for 15 min at room
temperature in the dark. After washed, and the volume of cells
was increased to 400 µl with binding buffer for analysis by flow
cytometry.
TLR-Binding Assay
Macrophages isolated from wild type, TLR2−/− and TLR4−/−
mouse were grown overnight on coverslips and then incubated
for 30 min at 37◦Cwith Rv1016c (20µg/ml) in Hank’s buffer. For
flow cytometer, after washed with PBS and fixed for 15 min using
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 3 November 2016 | Volume 6 | Article 147
Su et al. Rv1016c Regulates Innate Immunity
4% paraformaldehyde, the cells were stained with mouse anti-His
IgG conjugated with Alexa 488 (Santa Cruz Biotechnology), then
the cells were collected and 10,000 total events per sample were
analyzed by using a BD FACScan calibrator (BD Biosciences,
San Jose, CA). For confocal microscopy assay, macrophages were
stained with anti-Rv1016c and anti-mouse TLR2 for 2 h at 37◦C
in PBS containing 2% BSA. After washing, the cells were stained
with appropriate Alexa 488− or Alexa 555-conjugated secondary
antibodies for 1 h at 37◦C, and then they were incubated with 0.1
µg/ml DAPI for 5 min at room temperature. Finally, cells were
mounted on slides using Mowiol solution (Sigma-Aldrich) and
observed using a 63x oil objective on an LSM 710 microscope
(Carl Zeiss, Munich, Germany).
Immunoprecipitation Assay
Macrophages from WT, TLR2−/− or TLR4−/− mouse were
incubated with Rv1016c (20 µg/ml) for 6 h and lysed with RIPA
lysis buffer (Sangon, China). The lysates were pre-cleared by
adding protein A or G sepharose beads (Santa Cruz, CA, USA)
for 2 h. After centrifugation at 10,000 × g for 5 min at 4◦C, the
supernatant was incubated with Isotype IgG, anti-TLR2 or anti-
His overnight at 4◦C. After harvested and washed, the beads were
boiled in 5x sample buffer for 5 min. The proteins were separated
on 10% SDS-PAGE and probed with anti-TLR2 (BioLegend, CA,
USA), or anti-His Abs (Santa Cruz, CA, USA) as indicated,
followed by incubation with HRP-conjugated mouse anti-rat or
rabbit anti-mouse IgGAbs. Immunoreactive bands were detected
using an ECL reagent (Thermo Fisher Scientific, MA, USA) and
visualized by exposure to x-ray film.
Detection of MHC-II Expression by Flow
Cytometry
MHC-II expression assay was performed as previously described
(Noss et al., 2001). Macrophages (2 × 106cells/well in a 6-well
plate) were cultured for 24 h with 15 ng/ml IFN-γ, and then
cultured for 24 or 48 h with IFN-γ with or without Rv1016c
protein (20 µg/ml). Cells were harvested by vigorous pipetting
and trypsinization, incubated for 30 min on ice with Fc Block
(BD Pharmingen) at 1/100 in PBS with 0.1% BSA and for 1 h on
ice with FITC-conjugated anti-MHC-II (e Bioscience), or isotype
negative control Ig G (e Bioscience). After washed three times in
PBS, cells were analyzed with a BD FACScan flow cytometer.
Ag Processing and Presentation Assays
Ag processing and presentation assays were performed as
previously described (Noss et al., 2001). Macrophages (5 ×
105cells/well) were incubated with increasing concentrations of
Rv1016c protein or control buffer in the presence of 15 ng/ml
IFN-γ for 24 h. Then, cells were washed and incubated with
indicated concentration of OVA323−339for 3 h. After fixed in 1%
paraformaldehyde and washed extensively, the cells were finally
incubated with DOBWT hybridoma cells (1× 106/well for 24 h).
Supernatants from the T hybridoma assay were assessed for IL-2
using a CTLL-2 cell bioassay with a colorimetric determination
using Alamar Blue (Alamar Biosciences, Sacramento, CA) and
a Bio-Rad 550 microplate reader (Bio-Rad). Briefly, 5 × 103
CTLL-2 cells in 50 µl of complete DMEM were incubated with
100 µl of culture supernatant for 16–20 h. Proliferation of
CTLL-2 cells in each well was measured by a colorimetric assay
using Alamar blue (15 µl; Trek Diagnostics, Westlake, OH) and
a Versamax tunable microplate reader. Positive and negative
controls were included in each experiment to monitor CTLL-2
cell responsiveness. All data presented for Ag processing assays
compared controls with experimental conditions within the same
experiment, measuring the effects of lipoprotein exposure relative
to macrophages exposed to control buffer. IL-2 production was
expressed as OD at 550 nm minus OD at 595 nm.
For IL-2 level assay, macrophages (1 × 105cells/well) from
wild type, TRL2−/− or TRL4−/− were incubated with Rv1016c
(20µg/ml) or medium in the presence of IFN-γ (15 ng/ml) for 24
h at 37◦C. The cells were then washed with PBS and fixed for 20
min in in 1% paraformaldehyde. After Rv1016c antigen-specific
CD4+ T cells were isolated from mice immunized with Rv1016c
proteins, 1 × 106cells were co-cultured with macrophages for 48
h at 37◦C. Finally, the concentration of IL-2 in each supernatant
sample was examined using ELISA according to manufacturer’s
instructions. All results of experiments represent the mean
response of triplicate wells plus SD.
Western Blots
For Western blotting, equal amounts of protein were boiled
in SDS-PAGE sample buffer under reducing conditions, and
electrophoresed on 12% polyacrylamide gels. Protein was
transferred to polyvinylidene difluoride membrane (Millipore),
blocked in 5% BSA for 1 h at room temperature, and incubated
with primary Abs in PBS with 0.1% Tween 20 overnight at
4◦C, followed by incubation with horseradish peroxidase (HRP)-
conjugated secondary Abs for 1 h at room temperature. The
primary Abs included rabbit antiERK2, rabbit anti-p38, rabbit
anti-JNK, rabbit anti-phosphoERK1/2, rabbit anti-phospho-p38,
rabbit anti-phospho-JNK, and rabbit anti-phospho-IκB-α (Cell
Signalling Technology). The secondary Ab was goat anti-rabbit
IgG (Cell Signalling Technology). Pierce ECL Western Blotting
Substrate was used to assay target bands (Thermo Fisher
Scientific, Waltham, MA).
Quantitative PCR Assay of CIITA IV
Macrophages (2× 106cells/well) were incubated with or without
Rv1016c (20 µg/ml), and then with IFN-γ (15 ng/ml) in the
continued presence or absence of Rv1016c for various periods.
Block of the MAPK signaling pathway experiments involved the
pretreatment of THP-1 cells with inhibitors to p38 (SB203580,
10 µM), ERK (U0126, 10 µM), JNK (SP600125, 10 µM)
for 1 h at 37◦C, followed by incubation with Rv1016c for
36 h at 37◦C. Total RNA was obtained using the RNeasy
kit (Qiagen) and dissolved in RNase-free water. First-strand
cDNA was synthesized using the SuperScript preamplification
system (Life Technologies). The quantitative real-time PCR was
performed using a high-speed thermal cycler (LightCycler; Roche
Diagnostics, Indianapolis, IN), and product was assayed by
FastStart Master SYBR Green I (Roche Molecular Biochemicals,
Indianapolis, IN). All primers were synthesized by Sangon
(Shanghai, China), and their sequences were as follows: CIITA
IV sense, 5′-3′ACG CTT TCT GGC TGG ATT AGT; CIITA IV
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 4 November 2016 | Volume 6 | Article 147
Su et al. Rv1016c Regulates Innate Immunity
antisense, 5′-3′- TCAACGCCAGTCTGACGAAGG; GAPDH,
sense, 5′–3′ AACGACCCCTTCATTGAC, and antisense, 5′–3′
TCCACGACATACTCAGCAC. RNA amount of genes were
normalized to the level of GAPDH in each sample.
Statistical Analysis
All experiments were repeated 3 times at least with consistent
results, which were calculated as themean± SD of 3 experiments.
Statistical analysis was performed using a one-way ANOVA
followed by Tukey’s test using the origin 8.0 software (Origin
Lab, USA). For all tests, p ≤ 0.05 was considered statistically
significant.
RESULTS
Rv1016c is Associated with Mycobacterial
Cell Wall
To define whether Rv1016c is essential for MTB pathogenesis,
the Rv1016c gene was firstly amplified fromMTBH37Rv genome
DNA to generate E.coli BL21_PET28_ Rv1016c strains expressed
a 6x his-tagged Rv1016c protein (Figure 1A). Western blotting
also confirmed that the Rv1016c protein (∼24 kDa Rv1169c-
His protein) was successfully produced from E.coli BL21_PET28_
Rv1016c (Figure 1B). Secondly, the recombinant M. smegmatis
strains were used to investigate the role of Rv1016c. The semi-
RT-PCR demonstrated that Rv1016c could only be detected in
Ms_Rv1016c (Figure 1C). Western Blot analysis using the anti-
Rv1016c antibody further confirmed only Ms_Rv1016c strain
expressed Rv1016c protein in the cell lysates, while absent in
Ms_pNIT strain (Figure 1D).
Finally, MTB H37Rv strain and recombinant Ms_Rv1016c
were subjected to cell fractionation experiments, followed by
Western blot analysis with anti-Rv1016c antibody, to determine
the location of Rv1016c. The results showed that Rv1016c
lipoproteins were present in the cell wall fraction, indicating
that Rv1016c may be associated with the cell wall similar to
the localization of Rv3425, as Rv2145c (cytoplasmic proteins)
was detected only in the cytoplasm (Figure 1E). Proteinase
K assays further confirmed the cell surface association of
Rv1016c, as the Rv2145c was not degraded at all (Figure 1F).
FIGURE 1 | Rv1016c is a cell Mycobacterial well-associated protein and exposes on cell surface. (A) The expression of Rv1016c-His tag in E.coli BL21
strain was detected by commassie blue staining. (B) Western analysis of solubilized and purified Rv1016c protein with anti-His Ab. (C) Detection of Rv1016c
expression in recombinant M. smegmatis using RT-PCR. (D) Western blot analysis was used to examine Rv1016c expression in recombinant M. smegmatis with anti-
Rv1016c antibody. (E) M. tuberculosis H37Rv and M. smegmatis strains expressing Rv1016c were subjected to fractionation experiments, and the Rv1016c protein
in different fractions was detected by Western blotting using anti-Rv1016c antibody. The expression of cytosolic Rv2145c (cytosolic) and Rv3425 (cell wall-associated
protein) were also detected by anti-Rv2145c antibody or anti-Rv3425 antibody as a negative or positive control. Lane1: whole-cell lysate; lane 2: cytoplasmic
membrane fraction; lane 3: cytosolic fraction; lane 4: cell wall fraction. (F) M. tuberculosis H37Rv and Ms_Rv1016c strains expressing were digested by proteinase K
for the indicated times (0, 10, 20, and 30 min). The samples were analyzed for the expression of Rv1016c by Western blotting using anti-Rv1016c antibody. Rv2145c
and Rv3425 were analyzed by Western blotting as a control.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 5 November 2016 | Volume 6 | Article 147
Su et al. Rv1016c Regulates Innate Immunity
Taken together, these results demonstrate that Rv1016c may
be a cell wall-associated lipoprotein and exposed at the cell
surface.
Rv1016c Enhances the Survival of the
Recombinant M. smegmatis within
Macrophages and Promotes the
Resistance to Stress Factors
To examine whether Rv1016c can modulate the intracellular
mycobacterial invasion, growth and survival, we compared the
growth rate of Ms_Rv1016c and Ms_pNIT in macrophages.
The infection experiment was carried out at an MOI of 10 (10
bacterium per 1 macrophages). Our results demonstrated that
macrophages infected with Ms_pNIT and Ms_Rv1016c show the
same invasion ratio (Figure 2A), and there was no significant
difference in growth rates of the two strains (Figure 2B).
However, Ms_Rv1016c showed significantly higher bacillary
counts in THP-1 cells 24–72 h after infection (Figure 2C). The
results demonstrate that the presence of Rv1016c does not
influence uptake but can enhance the intracellular survival ofM.
smegmatis within macrophages.
To further determine how Rv1195 enhanced the intracellular
survival in macrophages, we compared the survival rate of
the Ms_pNIT and Ms_Rv1016c under stresses in vitro. As
shown in Figure 2D, the survival percentage of Ms_Rv1016c
was significantly higher than Ms_pNIT under acid stress
(pH = 3). For reactive oxygen resistance assay, the square
of the zone was smaller in Ms_Rv1016c than those of the
Ms_pNIT after H2O2 treatment (Figure 2E). Moreover, the
percentage of survival of Ms_Rv1016c was significantly higher
than that of Ms_pNIT after SDS treatment (Figure 2F). These
findings indicate that Rv1016c may be involved in virulence,
leading to increased resistance to stresses during mycobacteria
infection.
Rv1016c is a Ligand for TLR2
Although recognition of mycobacterial lipoproteins such as Lpq
H, Lpr G, and Lpr A are known to signal through TLR, Rv1016c
has not been tested for TLR ligand activity. To analyze whether
Rv1016c can bind to TLR2,macrophages fromWT, TLR2−/− and
TLR4−/− mice were incubated for 24 h with Rv1016c. Cells were
then stained with mouse anti-His IgG conjugated with Alexa
488. Flow cytometry analysis showed that Rv1016c bound to the
surface of WT and TLR4−/− mouse macrophages but not to the
surface of TLR2−/− cells (Figures 3A,B). Immunofluorescence
analysis also showed strong fluorescence of anti-Rv1016c on
the surface of WT, and TLR4−/− mice cells exposed to
Rv1016c but no fluorescence on the surface of TLR2−/−
macrophages cells (Figure 3C). To further ascertain whether
Rv1016c physically binds to the TLR2 molecule, we conducted
an immunoprecipitation assay using whole-cell extracts from
THP-1 cells. Western blots probed with anti-TLR2 showed that
Rv1016c was able to interact with TLR2. No band was visible
in the beads alone group or Rv1016c alone group (Figure 3D).
These results demonstrate that Rv1016c interacts specifically and
predominantly with TLR2.
FIGURE 2 | Rv1016c promotes intracellular survival of M. smegmatis
and boost the recombinants resistance to stress factors within
macrophages. (A) THP-1 cells were infected with Ms_pNIT or Ms_Rv1016c
at an MOI of 10 at day 0 (4 h post-infection). Invasion ratio is the ratio of the
number of intracellular bacteria and the number of initial infection bacteria. (B)
Growth of Ms_Rv1195 and Ms_pNIT strains at 37◦C in 7H9 liquid medium
were assayed by OD600 value in every 4 h. (C) THP-1 cells were infected with
Ms _pNIT or Ms_Rv1016c at the MOI of 10. After infection, Lysates containing
the live bacteria were diluted gradually and then plated on 7H10 agar plates to
determine bacteria number. (D) Growth of Ms _pNIT or Ms_Rv1016c under
Low pH (pH = 3) was measured in vitro. The bacteria were collected by
centrifugation and resuspended to an OD600 of 0.8 in 20 ml 7H9. The cultures
were incubated at 37◦C and 0.1 ml removed for viable count enumeration.
(E,F) Growth of Ms _pNIT or Ms_Rv1016c under stress conditions. Disk
diffusion method was used to measure the survival of recombinant
Ms_Rv1016c when exposure to SDS (E) and H2O2 (F). All results were
generated from three independent experiments and Data are shown as Means
± SD of triplicate wells. (*p < 0.05, **p < 0.01, ***p < 0.001, determined by
Student’s t-test).
Rv1016c Induces Macrophages Apoptosis
through TLR2
To detect whether Rv1016c induces macrophages apoptosis,
THP-1 cells or monocytes derived macrophages (MDMs) were
treated with a range of concentrations of recombinant Rv1016c.
Apoptosis was determined by flow cytometric analysis of
annexin V-PE binding or by TUNEL assay. As shown in
Figure 4A, increased levels of apoptosis were apparent with
20 µg/ml Rv1016c and continued to increase through 250
µg/ml, indicating that Rv1016c significantly induced apoptosis
both in THP-1 cells and MDMs in a dose dependent manner.
Apoptosis kinetics analysis showed that 20 µg/ml Rv1016c
significantly induced apoptosis as early as 1 h after exposure and
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FIGURE 3 | Rv1016c interacts with TLR2, but not with TLR4. (A,B) Macrophages derived from WT, TLR2−/−, and TLR4−/− mice were incubated with
Rv1016c-His (20 µg/ml) for 1 h, followed by incubation with Alexa488-conjugated anti-His Abs. After washing and staining, flow cytometry was used to examine the
binding between Rv1016c and TLR2. (C) Macrophages derived from WT, TLR2−/−, and TLR4−/− mice were treated with Rv1016c (20 µg/ml) for 1 h, fixed and
stained with primary antibodies (mouse anti-Rv1016c, rat anti-mouse TLR2), followed by incubation with appropriate Alexa488- or Alexa555-conjugated secondary
antibodies. Cells were photographed under fluorescence microscopy (original magnification × 63). Scale bar = 10 µm (D) Cells were incubated with Rv1016c
immobilized on Ni-NTA beads for 6 h, and proteins were visualized by Western blotting with anti-His or anti-TLR2 Abs to assay the presence of TLR2 with bead bound
proteins. All data were generated from three independent experiments and Data are shown as Means±SD of triplicate wells. (***p < 0.001, determined by
Student’s t-test).
continued to increase through 24 h (Figure 4B). Recombinant
Rv1016c–induced apoptosis was specific, as the frequency of
annexin V-PE-positive cells after treatment with the Histagged
β-galactosidase was similar to that observed for untreated
control cells (Figure 4C). In addition, to exclude whether LPS
contamination leads to apoptosis, the recombinant Rv1016c
protein was exposed to either heat treatment or to polymyxin B
before addition to cells. As shown in Figure 4D, LPS- induced
apoptosis changed little due to its resistant to heat treatment not
its sensitive to polymyxin B. In contrast, the apoptotic effects
of recombinant Rv1016c protein were completely abrogated
after heat treatment. We further determined the role of TLR2
in Rv1016c-induced apoptosis. THP-1 cells were incubated
with Isotype IgG, anti-TLR2 Abs or anti-TLR4 Abs for 18
h before Rv1016c treatment, and apoptosis was analyzed as
previously described. As shown in Figure 4E, incubation with
anti-TLR2 Abs significantly abrogated the proapoptotic effects
of Rv1016c lipoprotein. Similarly, when compared with wild
type or TLR4 knockout cells, apoptosis induced by Rv1016c was
completely abrogated in TLR2 knockout cells (Figure 4F). Taken
together, these results indicate that Rv1016c-induced apoptosis is
dependent on TLR-2.
Rv1016c is Able to Inhibit IFN-γ-Induced
Expression of MHC-II in Macrophages
Prolonged incubation of macrophages with mycobacterial
lipoproteins modulates IFN-γ-induced MHC-II expression and
antigen-presentation activity (Pennini et al., 2006). To clarify
whether the Rv1016c lipoprotein regulates MHC-II expression,
IFN-γ-stimulated THP-1 cells were treated with or without
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FIGURE 4 | Rv1016c induces apoptosis through TLR2 in macrophages. THP-1 cells or monocytes derived macrophages (MDMs) were incubated with either a
range of concentrations of Rv1016c for 2 h (A) or for varying lengths of time with 20 µg/ml recombinant protein (B). Apoptosis was analyzed by flow cytometry or
TUNEL assay. Actinomycin D was used as a positive control for apoptosis. (C) Apoptosis induced by Rv1016c is not due to His tag. THP-1 cells were incubated with
equal amounts of His-tagged β-galactosidase (as control for specificity) or His-tagged Rv1016c. Apoptosis was analyzed by flow cytometry. (D) Apoptosis induced by
Rv1016c is not due to LPS contamination. THP-1 cells were incubated with recombinant Rv1016c or LPS. Before addition to cells (20 µg/ml for 2 h), His-tagged
Rv1016c was either subjected to boiling for 1 h or treated with polymyxin B resin. For the latter, 100 µl of polymyxin bead slurry was added to 100 µl of recombinant
Rv1016c preparation and incubated at 4◦C for 1 h. After centrifugation, the supernatant was used for apoptosis induction analyzed by flow cytometry or TUNEL
assay. (E) THP-1 cells were incubated with Isotype Ig G (30 µg/ml), Anti-TLR2 blocking Abs (30 µg/ml) or Anti-TLR4 blocking Abs (30 µg/ml) for 18 h, followed by
treated with 20 µg/ml recombinant Rv1016c for 2 h. Apoptosis was analyzed by flow cytometry. (F) Macrophages derived from C57BL/6, TLR2−/−, and TLR4−/−
mice were incubated with Rv1016c-His (20 µg/ml) for 2 h, and then apoptosis was analyzed flow cytometry or TUNEL assay. Incubation of cells with actinomycin D or
Histagged β-galactosidase was used as a control for apoptosis. All data were generated from three independent experiments and Data are shown as Means ± SD of
triplicate wells. (*p < 0.05, **p < 0.01, ***p < 0.001 vs. corresponding controls).
Rv1016c for 24–48 h, and then flow cytometry was used
to analyze MHC-II expression. As shown in Figure 5A, the
level of MHC-II was low in Rv1016c-pusled macrophages
compared to cells cultured in medium, indicating that Rv1016c
lipoprotein inhibited IFN-γ–enhanced MHC-II expression.
Similar observations were also made for the endogenous MHC
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FIGURE 5 | Rv1016c inhibits IFN-γ-induced MHC-II expression and Ag
processing. (A) THP-1 cells were stimulated with IFN-γ (15 ng/ml) for 24 h at
37◦C, and then treated with or without Rv1016c-His (20 µg/ml) for 24 (left) or
48 h (right). Cells were incubated with FITC-conjugated anti-MHC II, or isotype
Ig G control Abs for 30 min in the dark room. MHC-II expression was analyzed
with a BD FACScan flow cytometer. (B) THP-1 cells were incubated with
medium, Rv1016c (20 µg/ml, 50 µg/ml) or rMPT8 (20 µg/ml, 50 µg/ml, as a
positive control) in the presence of with IFN-γ (15 ng/ml). MHC II mRNA levels
were measured by qPCR. (C) THP-1 (1 × 106 cells /well) were incubated with
increasing concentrations of Rv1016c or control buffer for 24 h in the presence
of IFN-γ (15 ng/ml). Then, cells were washed and incubated with OVA323−339
(800 ng/ml) for 3 h. After fixed in 1% paraformaldehyde and washed
extensively, the cells were finally incubated with DOBW T hybridoma cells (1 ×
106/well for 24 h). Supernatants from the T hybridoma assay were assessed
for IL-2 using a CTLL-2 cell bioassay. (D) THP-1 cells were incubated with
100µg/ml Rv1016c in the presence of IFN-γ (15 ng/ml), After 24 h incubation,
cells were pulsed with increasing concentrations of OVA323−339 for 3 h. Ag
processing was measured with DOBW T hybridoma cells as previously
described. (E) HLA-DR1-positive MDMs were treated with increasing
concentrations of Rv1016c or control buffer for 24 h. Following incubation with
Rv1016c, macrophages were pulsed with OVA323−339 (800 ng/ml) for 3 h. Ag
processing was measured with DOBW T hybridoma cells as previously
described. (F) HLA-DR1-positive MDMs were incubated with 100 µg/ml
Rv1016c in the presence of IFN-γ (15 ng/ml), After 24 h incubation cells were
pulsed with indicated concentration of OVA323−339 for 3 h and fixed. Ag
processing was measured with DOBW T hybridoma cells as previously
described. Data points represent the mean of triplicate samples with SD and
each panel is representative of at least two independent experiments.
(*p < 0.05, **p < 0.01 vs. corresponding controls).
II mRNA levels in THP-1 cells (Figure 5B). To further assess
whether Rv1016c affects the ability of Ag processing and
presentation of mouse macrophages, THP-1 cells or monocyte-
derived macrophages (MDMs) were incubated for 24 h with or
FIGURE 6 | Inhibition of MHC-II expression and Ag processing by
Rv1016c lipoprotein is dependent on TLR 2. (A) THP-1 were
pretreated with Isotype Ig G (30 µg/ml) or Anti-TLR2 blocking Abs (30 µg/ml)
for 18 h, followed by treated with IFN-γ (15 ng/ml) for 24 h at 37◦C, and then
treated with or without Rv1016c-His (20 µg/ml) for 24 h. Cells were then
incubated with FITC-conjugated anti-MHC II or isotype Ig G control Abs for 30
min in the dark room. MHC-II expression was washed and analyzed with a BD
FACScan flow cytometer. (B) Macrophages from WT, TLR2−/− or TLR4−/−
mice were stimulated with IFN-γ (15 ng/ml) for 24 h at 37◦C, and then treated
with or without Rv1016c-His (20 µg/ml) for 24 h. MHC-II expression was
measured as previously described. 1MFV was calculated as the MFV of cells
stained with anti–MHC-II minus the MFV of cells stained with the
isotype-control Ab. (C) Macrophages from WT, TLR2−/− or TLR4−/− mice
were stimulated with IFN-γ (15 ng/ml) for 24 h at 37◦C, and then treated with
or without Rv1016c-His (20µg/ml) for 24 h. Then, cells were washed and
incubated with indicated concentration of OVA323−339 for 6 h. After fixed in
1% paraformaldehyde and washed extensively, the cells were finally incubated
with DOBW T hybridoma cells for 24 h. Supernatants from the T hybridoma
assay were assessed for IL-2 using a CTLL-2 cell bioassay. (D) THP-1 cells
(1 × 105cells/well) were pretreated with Isotype Ig G (30 µg/ml), Anti-TLR2
blocking Abs (30 µg/ml) or Anti-TLR4 blocking Abs (30 µg/ml) for 18 h, and
then incubated with or without Rv1016c (20 µg/ml) in the presence of IFN-γ
(15 ng/ml) for 24 h at 37◦C. After washed with PBS and fixed in 1%
paraformaldehyde, Rv1016c Ag-specific CD4+ T cells (1 × 106cells/well)
were added to the plates, and were co-cultured for 48 h at 37◦C. ELISA was
used to assay the level of IL-2 in supernatant. (E) Macrophages
(1 × 105cells/well) from wild type, TRL2−/− or TRL4−/− mice were
incubated with Rv1016c (20 µg/ml) or medium in the presence of IFN-γ (15
ng/ml) for 24 h at 37◦C. Cells were washed with PBS and fixed for 20 min in
1% paraformaldehyde. Then, 1 × 106cells/well Rv1016c antigen-specific
CD4+ T cells were co-cultured with macrophages for 48 h at 37◦C. IL-2
level was assayed as previously described. All data were generated from
three independent experiments and Data are shown as Means ± SD of
triplicate wells. (**p < 0.01, ***p < 0.001 vs. corresponding controls).
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without Rv1016c, exposed to OVA323−339 for 3 h, fixed, and
incubated with DOBWT hybridoma cells for 24 h. IL-2 secretion
was determined using a CTLL-2 assay. The results showed
that exposure of macrophages to increasing concentrations
of Rv1016c for 24 h inhibited MHC-II Ag processing of
OVA323−339(Figures 5C,E). Kinetic analysis demonstrated that
substantial inhibition was first noted at 300 ng/ml with almost
complete inhibition by 2000 ng/ml OVA323−339 (Figures 5D,F).
These findings may identify Rv1016c as an inhibitor of MHC-II
expression and Ag processing.
Rv1016c Inhibits MHC-II Ag Processing
Dependent on TLR-2
To examine whether Rv1016c inhibits MHC-II Ag processing
through TLR2, THP-1 cells were pretreated with Isotype Ig
G (30 µg/ml) or Anti-TLR2 blocking Abs (30 µg/ml) for
18 h, followed by treated with IFN-γ (15 ng/ml) for 24
h at 37◦C, and then treated with or without Rv1016c-His
(20 µg/ml) for 24 h, flow cytometry was finally used to
analyze. As shown in Figure 6A, Rv1016c-mediated inhibition
of IFN-γ-induced MHC-II expression was reversed in those
macrophages, which were incubated with blocking anti-TLR-
2 Abs. Additionally, Rv1016c lipoprotein decreased expression
of MHC-II by C57BL/6 and TLR4−/− mice but not TLR2−/−
mice (Figure 6B). To further assess whether Rv1016c affects the
ability of Ag processing and presentation via TLR2, macrophages
from wild type, TLR2−/− or TLR4−/− mouse were incubated
for 24 h with or without Rv1016c (20 µg/ml), exposed to a
range concentration of OVA323−339 for 3 h, fixed, and incubated
with DOBW T hybridoma cells. IL-2 secretion was determined
using a CTLL-2 assay. Inhibition of MHC-II Ag processing
of OVA323−339 was reserved in TLR2
−/− mouse macrophages
(Figure 6C). Furthermore, THP-1 cells were pretreated with
Isotype Ig G, Anti-TLR2 blocking Abs or Anti-TLR4 blocking
Abs for 18 h, followed by treated with or without Rv1016c
(20 µg/ml) for 24 h in the presence of IFN-γ (15 ng/ml),
and then incubated with Rv1016c-specific splenic CD4+ T
cells. Supernatant levels of IL-2 were measured using ELISA.
The result showed that Rv1016c-induced decrease in MHC-
II presentation of Rv1016c peptide was blocked by anti-TLR2
Abs but not by anti-TLR4 or the isotype Abs, as reflected by
increased IL-2 levels (Figure 6D). Similarly, Rv1016c inhibited
the processing and presentation of Rv1016c peptide by C57BL/6
and TLR4−/−macrophages but not TLR 2−/− macrophages
(Figure 6D). These findings indicate that Rv1016c lipoprotein
may inhibit expression of MHC-II molecules and the processing
of Ag for presentation to CD4+ cells dependent on TLR2,
independent on TLR4.
Rv1016c Inhibits IFN-γ-Induced CIITA
Expression by TLR2 and MAPK Signaling
As an essential IFN-γ-associated immuneregulator, class II
transactivator (CIITA) IV regulates MHC II expression. Previous
study demonstrated that 19-kDa lipoprotein inhibited the
expression of CIITA induced by IFN-γ. To determine whether
Rv1016c has similar effects on CIITA IV, we incubated
macrophages with Rv1016c for 18 h, and then treated the cells
with IFN-γ for the indicated time. As shown in Figure 7A,
CIITA expression induced by IFN-γ was inhibited by Rv1016c
treatment. In addition, we used macrophages from C57BL/6,
TLR2−/− or TLR4−/− mice to examine whether inhibition
of CIITA IV requires TLR2 signaling through. Q-PCR results
showed that the ability of Rv1016c to inhibit IFN-γ-induced
CIITA expression was abrogated in TLR2−/− macrophages
(Figure 7B).
MAPK signaling is the key mediators of TLR2 pathway.
In this context, MAPK was activated by Rv1016c incubation,
as reflected by the increased phosphorylation of p38, ERK,
and JNK (Figure 7C). To further determine whether MAPK
plays a key role in Rv1016c-mediated inhibition of CIITA
expression, we treated macrophages with p38 inhibitor
FIGURE 7 | Rv1016c inhibits IFN-γ- induced expression of CIITA
dependent on TLR2 and MAPK pathway. (A) THP-1 cells were incubated
with or without Rv1016c-His (20 µg/ml) for 24 h, then with IFN-γ (15 ng/ml) in
the continued presence or absence of Rv1016c for the indicated times. RNA
was isolated, and quantitative real-time PCR was used to analyze the
expression of CIITA. (B) Macrophages (1 × 106cells/well) from wild type,
TRL2−/− or TRL4−/− were incubated with or without Rv1016c-His (20µg/ml)
for 24 h, then with IFN-γ (15 ng/ml) in the continued presence or absence of
Rv1016c-His for the indicated times. The expression of CIITA was measured
as previously described. (C) Rv1016c activates MAPKs pathway in
macrophages. THP-1 cells were treated with Rv1016c (20 µg/ml) or
Pam3CSK4 (5 µg/ml) for 1 h, the phosphorylation of p38, ERK (1/2) and JNK
were examined by blotting with specific antibodies to p-p38, p38, p-ERK1/2,
ERK1/2, p-JNK, and JNK. (D) Rv1016c-mediated inhibition of CIITA
expression is dependent on MAPK signaling. Macrophages were incubated
with or without DMSO (vehicle control), p38 (SB203580, 10 µM), ERK (U0126,
10 µM), or JNK (SP600125, 10 µM) for 1 h at 37◦C. Rv1016c (20 µg/ml) was
added to samples for the next 6 h, and IFN-γ (15 ng/ml) was added for a final
5 h (presence of inhibitors maintained). Expression of CIITA mRNA was
assayed as previously described. All samples were first normalized to GAPDH
and are expressed as the fold change compared with untreated controls. All
data are expressed as the mean ± SD from three separate experiments.
(*p < 0.05, **p < 0.01, ***p < 0.001 vs. corresponding controls).
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(SB203580), ERK1/2 inhibitor (U0126), JNK inhibitor
(SP600125) for 1 h prior to stimulation with Rv1016c.
Levels of CIITA IV mRNA expression induced by IFN-γ
was measured by Q-PCR. As shown in Figure 7D, three
inhibitors could attenuate Rv1016c-mediated inhibition of
CIITA IV expression. These results indicate that Rv1016c may
inhibit CIITA IV expression dependent on TLR2 and MAPK
signaling.
DISCUSSION
MTB genome encodes about 100 putative lipoproteins,
which may have critical functions ranging from interfering
mycobacterial virulence, generating antigenic variation and
evading host immune responses (Sutcliffe and Harrington,
2004). LppX is involved in the correct localization of phthiocerol
dimycocerosates (PDIMs), an important virulence factor of
M. tuberculosis. LprG binds triacylated phospho-inositol-
mannoside (PIM), lipomannan (LM) and lipoarabinomannan
(LAM) involved in the inhibition of phagosome-lysosome
fusion (Drage et al., 2010; Martinot et al., 2016). However,
several mycobacterial lipoproteins form immunodominant
antigens can promote protective immune response (Becker
and Sander, 2016). Immunization with recombinant MPT83 or
DNA-Mpt83 developed a strong IFN-γ secreting CD4+ T-cell
response, and significantly decreased the bacterial load in lung
and spleen as compared to control mice (Chen et al., 2012).
The interaction between mycobacterial lipoproteins and host
cells involved Toll-like receptor 2 (Pecora et al., 2006; Chambers
et al., 2010), which plays an important role in the elaboration of
protective Ag processing and inflammatory cytokines (Zeytun
et al., 2007; Saraav et al., 2014). As the key roles of lipoproteins
and TLR2 during MTB infection, the identification of novel
MTB lipoproteins, which bind to TLR2, contributes to deep
understanding the interaction between the pathogen and APCs
where it resides (Drage et al., 2009). In this context, we identified
Rv1016c as a mycobacterial cell wall -associated lipoprotein.
In addition, the affinity column pull downs using Rv1016c
immobilized on Ni-NTA beads followed by western blotting
analysis with anti-TLR2 antibody confirmed that Rv1016c
physically interacted with TLR2. Moreover, Rv1016c could
enhance the survival of the recombinant M. smegmatis within
macrophages and promote the resistance to stress factors. Taken
together, MTB lipoproteins Rv1016c may be a novel TLR2 ligand
and involve mycobacterial virulence.
Mycobacteria tuberculosis has been shown to be capable of
causing monocytes and alveolar macrophages apoptosis in vitro,
and alveolar macrophages recovered from MTB patients also
showed an increased frequency of apoptosis (Placido et al., 1997;
Keane et al., 2000). Recently, considerable interest has emerged
in understanding how M. tuberculosis infection affects apoptosis
of immune cells and whether this contributes to pathogenesis.
In the present study, we investigated the potential role of the
cell wall-associated protein Rv1016c to induce macrophages
apoptosis. Our data showed that soluble Rv1016c alone was
able to induce macrophages apoptosis in a both dose- and
time-dependent manner, and this effect was specific not due
to the His-tag or LPS contamination. TLR2 has been shown
to involve apoptosis induced by MTB ligands, and we further
examined whether induction of macrophages apoptosis by
Rv1016c is TLR2 dependent. The results showed that apoptosis
induction by Rv1016c was abrogated in TLR2−/− mouse
macrophages or THP-1 cells treated with anti-TLR2 blocking
Abs, indicating that Rv1016c may be an apoptosis-inducing
factor dependent on TLR2. Taken together, Rv1195 could
promote the survival of recombinant M. smegmatis and induce
apoptosis of host cells, consistent with the effect of MTB19-kDa
lipoprotein on macrophages (Lopez et al., 2003), indicating that
Rv1016c-induced apoptosismay lead tomycobacterial cell-to-cell
spread, and the increased survival of mycobacteria during the
infection.
MHC-II molecules continuously expressed in response to
infection can load with antigenic peptides in the MHC
compartment, and then export to the plasma membrane,
where they prime CD4+ T cells (Forsyth and Eisenlohr,
2016). Transcriptional control of MHC-II expression may be
a molecular basis of immune surveillance, through which
APC functions are regulated by M. tuberculosis protein
during infection (Ramachandra et al., 2009). Actually, MHC-
II expression can be regulated by cytokines like IFN-γ or
TLRs ligands in macrophages during MTB infection (Stern
and Santambrogio, 2016). Some Mycobacterial lipoproteins
such as (LpqH and LprG) were found to suppress MHC-II
expression via TLR2 in macrophages (Stewart et al., 2005; Shukla
et al., 2014). Similarly, in this study, Rv1016c was able to
inhibit IFN-γ-induced MHC-II expression and attenuated Ag
processing and presentation of macrophages, as reflected by a
decrease in IL-2 production (Figure 5). Additionally, Rv1016c-
mediated Inhibition of MHC-II expression and Ag processing
was reserved in TLR2−/− mouse macrophages or THP-1
cells blocked by anti-TLR2 Abs (Figure 6). Moreover, Rv1016c
lipoprotein inhibited IFN-γ-induced MHC-II expression by
preventing induction of class II transactivator (CIITA) IV in
a TLR2 dependent mechanism (Figure 7). Together, Rv1016c-
mediated inhibition of MHC-II expression and Ag processing
may lead to the prevention of Ag presentation and the decreased
recognition by CD4+ T cells. This may provide a mechanism
by which intracellular bacilli are able to evade immune
surveillance, survive under stress factors and maintain chronic
infection.
In this study, we find that cell wall-associated lipoprotein
Rv1016c may be a novel TLR2 ligand and may involve
mycobacterial virulence by enhancing survival of recombinant
M. smegmatis within macrophages and increasing resistance
to stress factors. Rv1016c may be an apoptosis-inducing
factor, and able to promote mycobacterial cell-to-cell spread
during infection. Moreover, we determine that Rv1016c
lipoprotein may inhibit IFN-γ-induction of MHC-II expression
and Ag processing by decreased IFN-γ-induced CIITA IV
expression via TLR2 and MAPK signaling. In the context
of tuberculosis, we propose that Rv1016c lipoprotein can
induce apoptosis, increase the survival of bacilli, and
decrease the presentation of MTB Ag to CD4+ T cells
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within human macrophages, allowing intracellular M.
tuberculosis to evade immune surveillance and promote chronic
infection.
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